Scarica l'app Stockscreener
15.36
3.21%
-0.51
Dopo l'orario di chiusura:
15.36
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
How to Take Advantage of moves in (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 5%Here's Why - MarketBeat
Short Interest in Tyra Biosciences, Inc. (NASDAQ:TYRA) Drops By 20.0% - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Shares Gap UpWhat's Next? - MarketBeat
RA Capital Management, L.P. Increases Stake in Tyra Biosciences Inc - GuruFocus.com
Tyra Biosciences to Present FGFR Precision Medicine Updates at Major Healthcare Conferences | TYRA Stock News - StockTitan
Equities Analysts Offer Predictions for TYRA FY2024 Earnings - MarketBeat
FMR LLC Increases Stake in Tyra Biosciences Inc - GuruFocus.com
Tyra Biosciences stock target cut, retains buy rating on clinical data - Investing.com Canada
HC Wainwright Has Lowered Expectations for Tyra Biosciences (NASDAQ:TYRA) Stock Price - MarketBeat
Tyra Biosciences director Nina Kjellson sells $1.28 million in stock By Investing.com - Investing.com Australia
Tyra Biosciences’ Q3 2024: Clinical Progress and Financial Resilience - TipRanks
Tyra Biosciences director Nina Kjellson sells $1.28 million in stock - Investing.com
Tyra Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - PR Newswire
Tyra Biosciences director Nina S. Kjellson sells shares worth $194k - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by Auour Investments LLC - MarketBeat
Long Term Trading Analysis for (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up After Insider Buying Activity - MarketBeat
Tyra Biosciences director Nina Kjellson sells $2.28m in stock By Investing.com - Investing.com Australia
Tyra Biosciences director Nina Kjellson sells $2.28m in stock - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Purchases $152,000.00 in Stock - MarketBeat
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock By Investing.com - Investing.com South Africa
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock - Investing.com
Tyra Biosciences (NASDAQ:TYRA) Trading Down 10.2%Here's What Happened - MarketBeat
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment By Investing.com - Investing.com Australia
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment - Investing.com
Piper Sandler maintains Overweight on Tyra Biosciences stock By Investing.com - Investing.com Canada
Tyra Biosciences stock target lifted, retains buy on clinical trial data - Investing.com Canada
Tyra Biosciences (NASDAQ:TYRA) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
FDA clears Tyra Biosciences' trial for dwarfism drug By Investing.com - Investing.com Australia
Tyra Biosciences (NASDAQ:TYRA) Price Target Raised to $32.00 at HC Wainwright - MarketBeat
FDA clears Tyra Biosciences' trial for dwarfism drug - Investing.com India
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - PR Newswire
Tyra Biosciences (NASDAQ:TYRA) Shares Gap DownWhat's Next? - MarketBeat
Tyra Biosciences' (TYRA) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Benzinga
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer - Marketscreener.com
(TYRA) Long Term Investment Analysis - Stock Traders Daily
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - PR Newswire
Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet - MSN
Tyra Biosciences (NASDAQ:TYRA) Sets New 52-Week HighWhat's Next? - MarketBeat
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - Marketscreener.com
Tyra Biosciences stock soars to 52-week high of $28.86 - Investing.com India
Tyra Biosciences stock soars to 52-week high of $28.86 By Investing.com - Investing.com South Africa
RA Capital Management, L.P. Reduces Stake in Tyra Biosciences Inc - Yahoo Finance
Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 19,084 Shares of Stock - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Shares Up 4.2%Here's Why - MarketBeat
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):